Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Theme
Exploring the advancements of Future Drug Discovery Research
- Drug Discovery 2023

Welcome message

It’s an immense pleasure to invite all participants from around the world to the 4th International Conference on Drug Discovery Chemistry will be held in Osaka, Japan, scheduled on March 13-15, 2023. We are excited about the opportunity to host a conference that combines creativity and reaches more audiences than a single conference can cover.

Drug discovery 2023 focus is on “Exploring the advancements of Future Drug Discovery Research” to enhance and expand the knowledge in drug discovery research. Convocation on drug discovery will provide the perfect platform to all the Professors, practitioners, researchers, and delegate people. At this conference, we arranged an immersive program that will show you the real worth of scientific conferences and it will be game-changing for your research ideas. The conference would be a major role in the research development field.

We feel glad and proud to say that our previous conference was fruitful and enjoyable and is held in Dubai and we hope that the upcoming event also would be the best one. We received very good reviews about our past conferences.

Followed by our successful conferences, drug discovery 2023 will bring together experts in clinical trials, pharmaceutical research, drug research-related industry people, research-supporting association, and healthcare people. The conference will be an extraordinary interview platform, where both young and experienced senior research people can expect long-term collaboration. It will also prove an open door to university people and young researchers.

This conference will be a great place to gather for upcoming drug discovery research. The advanced drug discovery systems, AI-integrated drug discovery processes, drug design, and Proteomics in drug Discovery would be the major role of our conference. We are sure this will be the platform for gathering and disseminating the latest knowledge on recent advances and research in research from the diverse research fields covered at the conference. A platform for participants to share experiences and insights through a variety of sessions, poster presentations, seminars, and presentations.

Join the drug discovery conference to meet the leading experts in drug discovery and
drug design research across the country, hear them share their experiences and insights on the most extreme drug discovery needs, and interact with medical researchers and leaders in the field of research that encompasses vast networks.

Drug discovery 2023 looks forward to meeting you in Osaka, worlds one of the most beautiful cities. Make the 4th annual conference on drug discovery 2023 an unforgettable occasion by joining us.

Session and Tracks

1.  Drug Discovery:

This research topic aims to publish data on recent advances in early drug discovery against emerging/neglected tropical diseases, including parasitic, bacterial, viral, and fungal infections. Here we collect valuable insights related to the development of new experimental approaches, the identification of novel therapeutic strategies, and the mechanism of action of classical or novel antibacterial agents. Over the past 40 years, the complexity of drug development has multiplied, necessitating the preclinical stage of drug research, an investigational new drug (IND) application, and extensive clinical testing before FDA marketing clearance. Successful drug discovery is like finding a safe and effective oasis in a chemical and biological desert. Analyzes based on the drug development approach show that the discoverability of suitable candidates is highly sensitive to the validity of predictions, as deserts are large and oases are small. Especially since drug development is very difficult to measure late in the process before the project succeeds or fails.


Discovery & Development
Preclinical research
Drug development process
Market monitoring


Related associations and Societies:

Drug Information Association | Alzheimer's Drug Discovery Chemistry Foundation | Drug Development Program association | Drug Development and Society | Pharmacology & Drug Discovery Chemistry Association | Drug Discovery and Development – Committee | Pharmacology and Drug Discovery Chemistry Society | European Federation of Drug Discovery Chemistry | European Association of Drug Discovery Chemistry and Drug Discovery Chemistry conference | American Association of Drug Discovery Chemistry and development


Related Conferences:

Drug Discovery conference and Screening conference | Development and Drug Discovery conference | Drug Discovery conference | Asian Drug Discovery conference | Drug Discovery conference and events | Drug Discovery conference  | Development and Drug Discovery conference | Modern Phenotypic Drug Discovery conference | ELRIG Drug Discovery conference | Medicinal Chemistry and Drug Discovery conference | Therapeutics and Vascular Pharmacology Conference | Pharmaceutical Sciences and Pharmacology Conference | Chemistry and Quantum Pharmacology conference | Neurology and Psychedelic Pharmacology Conference


2. Drug Screening:

The search for new medicines is a challenging process that is nevertheless gratifying. Drug discovery Chemistry research makes it possible. The first step in the procedure is to identify a condition or a therapeutic field with an unmet need. A "druggable" target is identified, and drug screening begins in the drug discovery process resulting from Small-molecule. Molecules that can interact with the target and/or support the intended phenotypic response are found during drug screening.
Additionally, professional athletes occasionally utilize performance-enhancing medications like HGH and steroids, which can be found during a drug test.
 The treatment of complex diseases such as cancer, cardiovascular disease, diabetes, and neuropathy often justifies the use of drug combinations for therapeutic intervention. However, identifying successful drug cocktails is not a trivial task and is hampered by a lack of standardization in terminology, experimental protocols and models, and data analysis that followed in drug development.


Target identification
Target validation and Lead Identification
Lead optimization
Preclinical safety


Related associations and Societies:

Drug Discovery Chemistry and Development Committee | American Association of Drug Discovery Chemistry and development | Development and Drug Discovery Predicting Drug-Disease Association | American Association of Pharmaceuticals Science | Drug Development Committee | The ALS Association | Pharmacology & Drug Discovery


Related Conferences:

Development and Drug Discovery conference | Drug Discovery  conference | Europe Drug Discovery conference | Drug Discovery conference and events | Drug Discovery conference | Drug Discovery conference and Development  | Modern Phenotypic Drug Discovery conference | ELRIG Drug Discovery conference | Medicinal Chemistry and Drug Discovery conference | Behavioral Techniques in Behavioral Pharmacology Conference | Toxicology and Endocrine Pharmacology Conference | Analytical Chemistry and Pharmacology conference |  Domestic Animals Parasitology, and Pharmacology Conference


3. Clinical Trials in Drug discovery:

Today, people are living longer because of the success of cancer treatments resulting from previous clinical trials. Through clinical trials and drug discovery, doctors determine whether new treatments are safe, effective, and better than current treatments. Participating in clinical trials broadens our knowledge about cancer and helps improve cancer care for future patients. In this way, clinical trials play a major role in the drug development and Drug Design process. Helps improve treatment. Clinical trials are key to advancing the fight against cancer. In today's global scientific age, clinical trials and drug Discovery are essential to bringing newer and better medicines to market. Clinical trials test potential treatments on human volunteers (subjects) to determine whether they should be approved for wider use in the general population. For the future of better healthcare, Clinical Trials are important.


Prevention trials
Treatment trials
case-control studies
Cross-sectional studies


Related associations and Societies:

British clinical trials society | Gene-disease Drug Discovery Chemistry association | Parenteral Drug Association | Natural Products and Drug Discovery Chemistry | Clinical trials Research and Drug Development Associations | Drug-Protein-Disease Association | Pharmaceuticals Research & Development | Opensource Drug Discovery Chemistry Association | African Drug Discovery Group


Related Conferences:

Medicinal Chemistry and Drug Discovery conference |  Drug Discovery conference & Development | Drug Discovery conference and Development | Clinical Trials Conference Medicinal Chemistry and Drug Discovery conference | GPCR-Targeted Drug Discovery conference | Induced Proximity-Based Drug Discovery conference | Advances in Brain Targeted Drug Discovery Conference | Cardiovascular Pharmacology and Drug Discovery Conference  | Ophthalmic Biomaterials and Drug Discovery Conference  | Nano-Drug Delivery Systems | Medicinal Chemistry and Drug Design | Nanotechnology and Drug Discovery Conference | Chemotherapeutic Drugs and Immunopharmacology Conference | Pharmacotherapy and  Nicotine Psycho Pharmacology Conference | Drug Development Pharmacology Conference | Physiology and Gastrointestinal Pharmacology Conference | Toxicology Research and Pharmacology Conference


4. Drug Formulation Technology:

Technological advances in excipient manufacturing, as well as advances in processing and manufacturing technology of drug design, have forced formulators to change the way they design new products. The need for safer, more consistent medicines shapes their decisions. Patient demand for medicines that are convenient and safe to take is increasing drug design. As a result, the pharmaceutical industry is inventing new types of tablets that combine multiple active ingredients. The airway of asthmatics is a battlefield of pervasive inflammation and environmental triggers to drug design. In addition to conventional therapies on behalf of drug development, new biologic therapies targeting IL-5 and other key interleukins are being used to control asthma and prevent fibrotic airway damage. A new frontier of asthma therapy was recently explored, based on tailor-made nanoparticles designed to deliver drugs under such conditions of drug design.


Excipients compatibility
Pre-formulation for early safety studies
Up-front stability testing
Development and validation of analytical methods


Related associations and Societies:

American Association of Pharmaceuticals Scientists | American Pharmacists Association | American Society of Health Systems and Pharmaceuticals | National Association of Boards of Pharmacology | National Community Pharmaceuticals Association | National Association of Chain Drug Stores | Pharmaceuticals Care Management Association | Drug Discovery Information Association | Drug Development Program association | Drug Development Society | Pharmacology & Development Research Association


Related Conferences:

Cancer Drug Discovery conference | Drug Discovery Conference and Development | Organs-on-Chips and Drug Discovery Conference | Translational Medicine and Drug Discovery Conference | Herbal Drug Discovery and Development Conference | Designing and Drug Discovery conference  | Innovative Approaches for Novel Antibacterial Drug Discovery Conference | Medicinal Chemistry and Drug Discovery Conference | Innovations in Drug Discovery Conference | Innovative Approaches in Drug Discovery Conference and Development | Technological Advancement in Drug Discovery Conference | Drugs and Gastrointestinal Pharmacology Conference | Toxicology and Medical Pharmacology  Conference | Therapeutics and Gastrointestinal Pharmacology Conference


5. Advanced Drug Delivery System:

In contrast to engineered nanosystems, biological systems are ideally designed to respond to their environment. Thus, natural molecular buffers ensure the precise and quantitative drug delivery of specific molecules through self-regulatory mechanisms. Here, we apply this principle to design autoregulatory molecular nucleic acid buffers for the chemotherapeutic drug doxorubicin and the antimalarial drug quinine. We show that these aptamer-based buffers can be programmed to maintain specific and desired free drug concentrations in vitro and in vivo, demonstrating drug development and drug chemical stability, partition coefficient, pharmacokinetics, and pharmaceutical biodistribution. Allows for optimization. These programmable buffers can be made from any polymer and should improve patient outcomes by enhancing drug activity, minimizing side effects, and dosing frequency.


Nasal drug delivery
Ocular drug delivery
Pulmonary drug delivery
Buccal drug delivery
Sublingual drug delivery
Transdermal drug delivery


Related associations and Societies:

Drug Discovery Information Association | Drug Development Program association | Drug Development Society | Pharmacology & Development Research Association | Drug Discovery and Development – Committee | Pharmacology and Drug Discovery Chemistry Society | American Association of Drug Discovery and development | Australian College of Pharmacology | Pharmaceutical Society of Australia | The Pharmacology Guild of Australia | The Society of Hospital Pharmaceuticals of Australia


Related Conferences:

Dermatology Drug Discovery conference | Development and Drug Discovery conference | Aging Research & Drug Discovery conference | International Conference on Drug Discovery Conference | Drug Discovery conference and Development – Committee | American Drug Discovery Conference | Nano biomaterials for Drug discovery Conference  |  Advances in Brain Targeted Drug Discovery conference | Cardiovascular Pharmacology Conference | Drug Discovery Conference | Ophthalmic Biomaterials and Drug Discovery Conference | Nanotechnology and Drug Discovery Conference | Medicinal Chemistry and Drug Discovery conference | Nanotechnology and Drug Delivery Conference 


6. Proteomics and Bioinformatics in Drug Discovery:

The development of modern sequencing drug discovery with technologies has greatly advanced biomedical data over the past decade, opening new windows in clinical diagnosis and treatment of complex diseases. Bioinformatics can extract, analyze, and communicate hidden information from sequence and structure as well as functional knowledge of nucleic acids and proteins to drug development. This may lead to the design of therapeutic agents that activate or block the biological functions of biomolecules and help build various predictive models to support virtual bioactivity screening. This will aid in the pharmaceutical design and drug development of safer and more efficient therapeutic agents that can activate or block the biological functions of biomolecules. Therefore, all of the above problems must be fundamentally addressed in the application of bioinformatics technology and the development of new drugs.


Structural biology
Transcriptomics                              
Ribosome profiling
Proteomics analysis


Related associations and Societies:

Pharmaceuticals Federation | National Association of Boards of Pharmacology | International Pharmaceuticals Scientists Federation | National Association of Pharmacology Regulatory Authorities | National Community Pharmaceuticals Association | Nonprescription Drug Manufacturers Association of Canada | Subsidiary Drug Discovery Chemistry Associations | Drug Discovery Information Association | Identification of Drug–Cancer Associations | Drug Discovery and Drug Development Society | Korean Pharmaceuticals Association


Related Conference:

Technological Advancement in Drug Discovery Conference | Drug Design, Development, and Pharmaceutical Conference |  and Development | Antibiotics, Drug Discovery conference | Antineoplastic Drug Discovery conference | Experimental Drug Discovery and Pharmacology Conference | Cancer Drug Discovery Conference | Aging Research & Drug Discovery conference | Biochemistry and Drug Discovery Conference | Dec Parasitology, Animal Science and Pharmacology Conference | Chemistry and Pharmacology Conference | Pain Management and Anesthetic Pharmacology Conference 


7. Pharmaceutical Formulation:

The delivery of therapeutics to the brain remains a challenge for researchers, and new methods of drug delivery continue to be explored in drug development. It provides a comprehensive overview of various nano-based drug delivery systems that aid in drug delivery across the blood-brain barrier. Inorganic nanocarrier systems, including gold and magnetic nanoparticles, as well as organic systems such as dendrimers, liposomes, niosomes, micelles, and polymeric nanoparticles, are discussed. A variety of commonly used nanoparticle drug design functionalization techniques for delivery to the brain include surface modification by physisorption using electrostatic forces, chemical cross-linking, covalent end-group modification, and layer-by-layer assembly techniques. Achieving an effect is not achievable when its ingredients are used individually. Achieve higher efficiency. They improve handling characteristics and many cases also improve user safety of drug discovery.


Related associations and Societies:

Drug Development and Drug Discovery Chemistry Program association | Drug Discovery Chemistry Society | Pharmacology & Drug Discovery Chemistry Research Association | Drug Discovery and Development – Committee | Pharmacology and Drug Discovery Chemistry Society | European Federation of Drug Discovery | European Association of Drug Discovery Chemistry | American Association of Drug Discovery Chemistry and development


Production of plasmid DNA vaccines
Oncological formulations
Parental formulations
Topical formulations
Novel drug formulations


Related Conferences:

Safety Pharmacology Conference | Drug Discovery Conference and Development | Development, and Drug Design Conference | Cancer Epigenetics and Drug Discovery Conference | Piperidine-Based Drug Discovery Conference | Safety and Pharmacology Conference  | Drug Development and Drug Discovery Conference |  Drug Discovery and Pharmacology conference | Drug Discovery Conference on Serotonin Pharmacology | Antineoplastic Drugs and Drug Discovery Conference | Piperidine-Based Drug Discovery Conference and Research | Drug Formulation, Bioavailability, and Pharmacology Conference | Placebo Effect and Pharmacology Conference | Nootropic Agents Chemistry and Pharmacology Conference | Pharmaceutical Management Conference

8. Medicinal Chemistry:
Diabetes has always been a major global health problem. Current treatments include oral and injectable hypoglycemic agents with specific toxic effects and side effects. Drug discovery and Medicinal chemistry provide a comprehensive understanding of the basic principles of drug action and behavior in the body that underlie today's pharmaceuticals care and patient counseling. Therefore, there is a growing need to discover more effective and safer antidiabetic drugs. Scientists have raised many concerns over the last few years in pharmaceuticals since discovering that apigenin is a non-toxic, edible, plant-derived flavonoid, with reduced bioavailability. Therefore, it is of great importance for pharmaceuticals to improve bioavailability by developing various derivatives through structural modifications by drug development. This overview lists various apigenin derivatives with different modifications of and synthetic methods handled in pharmaceuticals. We also analyzed and compared their antidiabetic activities. Meanwhile, several widely studied pharmaceuticals of antidiabetic mechanisms were summarized to better understand the antidiabetic effects of apigenin.

Basic aspects of drug activity
Analgesics and anti-inflammatory agents
Adrenergic drugs
Drug therapy
Antineoplastic agents


Related associations and Societies:

Pharmacology Federation of USA | National Association of Boards of Pharmacology | Pharmaceuticals Students' Federation | National Association of Pharmacology Regulatory Authorities | National Community Pharmacology Association | Nonprescription Drug Discovery Association of Canada | Pharmacology & Drug Discovery Research Association | Drug Discovery Chemistry and Drug Development – Committee | Pharmacology, and Development Society


Related Conferences:

Quantum Mechanics and Quantum Pharmacology Conference | Gastrointestinal Pharmacology and Drug Discovery Conference | Cancer Pharmacology and Treatment | Pharmacovigilance and Pharmacology Conference | Cognitive Enhancers and Pharmacology Conference | Veterinary Science, Surgery and Epizootiology | Advances in Veterinary Forensic Pharmacology Conference | Drugs and Nocebo Response in Pharmacology Conference | Drug Design Conference | Drug Discovery and  Pharmacology conference | Therapeutics and Pharmacology Conference | Medicinal and Biochemistry Conference | Drug Discovery conference


9. Machine Learning for Drug Discovery:

Nowadays machine learning and AI play an important role in drug discovery. Rapid and accurate prediction of molecular properties is critical to advancing scientific discovery and application in fields ranging from materials science to pharmaceuticals. The pharmaceutical Experiments and simulations to explore possible options are time-consuming and expensive, so scientists have explored the use of machine learning (ML) techniques to support computational chemistry and pharmaceuticals field research to make an additional impact on drug development. However, most ML models can only use known or labeled data. The pharmaceutical aspects make it nearly impossible to accurately predict the properties of new compounds. A new wave of drug Discovery and drug development platforms enabled by artificial intelligence is enabling companies to leverage massive datasets to rapidly identify markers of patient response and identify viable drug targets more cost-effectively. It helps you to develop efficient drug discovery. Machine learning techniques improve pharmaceutical data decision-making in a variety of applications, including Target validationdrug development, prognostic biomarkers, and digital pathology are considered under this review issue considered in the pharmaceutical field.


QSAR analysis 
De novo drug architecture                                            
                                                                                                                                          Diagnostic assistance

DMTA cycle


Related associations and Societies:

Behavioral Pharmacology and Applications | Synaptic Pharmacology and Pharmaceuticals Experimentation | Biomedical Engineering and Pharmacology Society | Experimental Pharmacology and Experimental Animals | Pharmacology, and Anesthesia Association | Pharmacology and Pharmaceuticals Drug Society | Pharmacology, Pharmacokinetics, and Pharmacovigilance | Developing Countries and Pharmacology Society | Korean Pharmaceutical Association | Drug Discovery Chemistry and Drug Development | Drug Discovery and Information Association | Drug Development and Drug Discovery Chemistry association | Pharmaceuticals & Drug Discovery Research Association


Related Conferences:

Experimental Brain Research and Psychopharmacology Conference |  Drug Discovery Conference | Advances in Endocrine Pharmacology Conference | Recent Advances in Pharmacology and Pharmaceutical Conference | Sedative Hypnotic Drug Discovery and Pharmacology conference | Recent Advances in Immunopharmacology and Pharmaceuticals Conference | Pharmacodynamics and Pharmacology Conference | Cholinergic Drugs and Serotonin Pharmacology Conference | RNA-Targeted Drug Discovery conference | Meridian Drug Discovery conference | Drug Development and  Drug Discovery conference


10. Nanomedicine:

Cancer immunotherapies, such as immune checkpoint inhibitors, have attracted attention in recent years as novel approaches to cancer treatment. But immune checkpoint suppression therapy is only successful in 20-30% of cancer patients. Therefore, it is urgent to discover improved drug delivery platforms to activate cellular antitumor immunity to make better drug development. Over the past decade, there has been an increasing need to develop multiple systems that can deliver active pharmaceutical ingredients precisely and specifically to the desired site. In the future, nanotechnology may allow us to receive personalized treatment also it will allow major play in drug discovery. Through drug development and drug research, newly developed nanomedicine includes, for example, multicomponent systems, so-called theragnostic, which can contain both therapeutic and diagnostic molecules.


Sepsis treatment
Nano diagnosis treatment
Controlled drug delivery
Regenerative medicine.

 


Related associations and Societies:

Pharmaceuticals Scientists Federation | Pharmaceuticals Regulatory Authorities | Pharmaceuticals Association  | Drug Discovery Association of Canada  | American Association of Pharmaceuticals Scientists | Association of the British Pharmaceuticals Industry  | American Chemical Society Division of Drug Design | Pharmacology & Drug Discovery Chemistry Research Association | Pharmacology and Drug Discovery Chemistry | Society Drug Development and drug design Society | Drug Development and Drug Discovery Committee


Related Conferences:

Pharmacovigilance and Pharmaceuticals Conference | Drug Discovery and Pharmacology Conference | Veterinary Science, Surgery and Epizootiology Drug Discovery Conference | Advances in Veterinary Forensic Toxicology  Drug Discovery Conference | Drugs and Nocebo Response in Pharmaceuticals Conference | Drug Design and Pharmacology Conference | Therapeutics and Pharmaceuticals Conference | Applications and Behavioral Pharmaceuticals Conference | Synaptic Pharmaceuticals and Pharmacology conference | Biomedical Engineering and Pharmaceuticals Conference | Drug Discovery conference | Development and Drug Discovery  conference | Development of  Drug Discovery conference


11. Biomarkers:

The past few decades have seen a significant advance in deciphering the pathophysiology of inflammatory bowel disease. Surprisingly, this abundance of treatment options does not yield the expected long-term response rates to increase drug design. Additionally, the increase in treatability has triggered an increase in research into biomarkers that may help designate therapy for patients most likely to respond in the drug design process. Fortunately, in the process of drug research, important steps have been taken in the Drug development area leading to the discovery of several interesting biomarkers that are still being validated. However, the pace of progress in the field, the mismatch between short-term endpoints in studies of drug design exploring biomarkers, the ambition of the disease community to change disease course, and the inability to have certainty about the validity of detected biomarkers underlines the need for critical evaluation to drug design and drug development. conduct drug Discovery research in this area. We have highlighted areas for improvement in drug discovery studies that will help optimize the use of available therapies and break the current treatment ceiling and drug design and drug development. The discovery of biomarkers for predicting treatment response in IBD is an area of ??prime importance, given the urgent need to break the current treatment ceiling. Still, understanding the interactions between drugs and the most complex of systems - intact beings - is the ultimate goal to make proper drug discovery and drug design.


Hybrid inhibitor designing
Drug repurposing
Pharma kinetics
Pharmacotherapeutics


Related associations and Societies:

American Society for Biochemistry and Molecular Biology | American Association for Clinical Biochemistry Chemistry | American Biochemistry Society | American Society for Biochemistry | Association of Medical Biochemistry | Australasian Association for Clinical Biochemistry | United Nations Association of Drug Development and Drug Discovery Chemistry  | Drug-Target Association Kinetics in Drug Discovery Chemistry | Subsidiary Biochemistry Associations | Drug Discovery and Information Association | Identification of  Cancer Drug Discovery Associations | Biochemistry and Drug Discovery Development | Biochemistry and Drug Discovery  Development Association.


Related Conferences:

Forest Tree Physiology and Biochemistry conference | Nutritional Biochemistry and Physiology Drug Discovery conference  | Medicinal Chemistry and Drug Discovery conference | Developmental Biology and Biochemistry Drug Discovery Conference | Plant Biochemistry conference  | Amino Acids and Biochemistry conference  | Glycobiology and Biochemistry Drug Discovery Conference  | Molecular Mechanisms and Veterinary Biochemistry conference | Domestic Animals Clinical Biochemistry conference  | Molecular Interactions and Quantum Biochemistry conference


12. Antibiotics:

The current model of antibiotic discovery is not delivering new drugs fast enough to combat current levels of antibiotic resistance. Scientific difficulties, an unfavorable regulatory environment, multiple mergers, and low economic returns associated with antibiotic development have driven many pharmaceutical companies out of the field. Although the drug research regulatory environment has improved since then, major scientific hurdles still hinder the discovery and development of new antimicrobial agents. With the increasing resistance of bacteria and the decline in the development of new antibiotics and drug research, the appropriate use of older antibiotics has become even more imperative. Clindamycin is a lincosamide antibiotic approved for adults and children as the drug of choice for systemic treatment in clinical trials of infections caused by anaerobic staphylococci, streptococci, and gram-positive bacteria. Because of its properties and high bioavailability, it is often used as part of an oral multimodal alternative to prolonged parenteral antibiotic regimens, for the treatment of infections associated with bones and joints or prosthetics. In addition, drug interactions derived from CYP3A4 inducers and inhibitors, and data on the impact of disease states on the CYP system, are still limited. These kinds of impacts make an important to drug discovery and drug development.


Mono bantams                                                                                                                                                                                                       Immunology

Antibiotic regiments
                                                                                                          


Related associations and Societies:

Society for Clinical Trials | Clinical Trials Research Association | Indian Society for Clinical Trials Research | Drug Discovery and Biochemistry Association | Drug Development and Biochemistry Program association | Drug Discovery Chemistry Development Society | Pharmacology & Drug Discovery Chemistry Research Association | Drug Discovery Chemistry and Development – Committee | Pharmacology Society of USA | Drug Discovery and Biochemistry Society


Related Conferences:

Anticancer Drug Development and Clinical Trials Conference | Advanced Clinical Research and Clinical Trials Conference  | Healthcare Wearable Technologies in Clinical Trials Conference | Drug Development Process and Clinical Trials Conference | Cardiology Clinical Trials Conference | Drug Development Technologies and Clinical Trial Conference | Cardiology Clinical Trials Conference | Development and  Drug Discovery  conference | Modern Phenotypic Drug Discovery conference | Drug Discovery conference | Medicinal Chemistry and Drug Discovery conference


13. Biopharmaceuticals and Synthetic Drugs:

Biopharmaceutical Classification System "BCS" To provide a scientific approach to the classification of drug compounds based on dose-related solubility and intestinal permeability in combination with the dissolution properties of oral immediate release (IR) dosage forms. The purity of the active ingredient in a pharmaceutical product and the composition of the final product can be verified relatively easily. High-purity chemicals from a variety of sources, including those formed from mixtures of isomers, can often be considered similar or even identical for practical purposes. The situation is different for biopharmaceuticals to conduct drug discovery. Due to biological differences between expression systems and the applied process conditions, some degree of variation can occur, even between different batches of the same product. Therefore, lot-to-lot variation should be monitored to ensure compliance. within a specific range, these aspects of Drug Discovery have implied. The properties of the active pharmaceutical ingredients in biopharmaceuticals, in addition to their primary structure (e.g., amino acid sequence), depend significantly on the manufacturing method. For this reason, it has been suggested that the "product identification procedure" for biopharmaceuticals 6, 7. Several protein expression systems have been established over the years, each with advantages and disadvantages.


Organs and tissues
Gene Therapy
Peptides components
Proteins in antibiotics


Related associations and Societies:

Drug Discovery and Development Program association | Drug Discovery Society | Pharmacology & Drug Discovery Research Association | Drug Discovery and Development – Committee | Pharmacology and Drug Discovery Society | European Federation of Drug Discovery | American Association of Drug Discovery | American Association of Drug Discovery and development.


Related Conferences:

Nano biomaterials for Drug Delivery Conference  | Advances in Brain Targeted Drug Delivery Conference | Cardiovascular Pharmacology and Drug Delivery conference | Ophthalmic Biomaterials and Drug Delivery Conference | Nano-Drug Delivery Conference | Medicinal Chemistry and Drug Design Conference | Nanotechnology and Drug Delivery Conference | Applications of Ocular Drug Delivery Conference | Applications of Nanotechnology in Drug Delivery Conference  | Applications of Ocular Drug Delivery Conference  | American Association of Biochemistry Conference

14. Computer-Aided Drug design-CADD:

With the rapid improvement of computational methods and high-performance computing resources, computer-aided drug design has proven to be an effective and powerful strategy in almost any Drug Discovery and development. Due to the rapid development of crystallography and homology modeling techniques, structure-based virtual screening has become a useful technique to identify potential hits in the early stages of drug discovery. In addition to drug discovery and drug design, computational techniques such as quantum computing, molecular kinetics (MD) simulations, and elastic lattice modeling can be used to study protein catalysis, structural transitions, and other processes. allosteric determinations at the atomic level, providing useful information for drug-based mechanisms patterns. In this special research, the topic illustrates the applications of the CADD method and highlights the importance of developing new methods in drug design and drug discovery.


Quantitative Structure-Activity Relation
Bioanalytic Testing
Pharmacophore
Binding affinity


Related associations and Societies:

Drug Discovery Program association | Drug Discovery and Development Society | Pharmacology & Drug Discovery | Drug Discovery Chemistry and Development – Committee | Pharmacology, and Drug discovery Society | Federation of Drug Discovery and Biochemistry | European Association of Drug Discovery Chemistry | American Association of Drug Discovery Chemistry and development


Related Conferences:

Europe Drug Discovery conference | Asian Drug Discovery conference | AI in Drug Discovery conference | Metabolomics in Drug Discovery conference | Cardiology and Drug Discovery conference | Immunology and Drug Discovery Conference | Drug Research & Drug Discovery conference | AI-Driven Drug Discovery conference | Forensic Toxicology and Pharmacology Conference | Animal Health and Veterinary Industrial Pharmacology Conference | Toxicology, Therapeutics, and Veterinary Industrial Pharmacology Conference | Veterinary Industrial Pharmacotherapy and Pharmacology Conference | Therapeutics Veterinary and Industrial Pharmacology Conference | Forensic Pharmacology Conference


15. Vaccine drug delivery systems:

Subunit immunization, although extremely specific and obvious in response to antibodies, does not usually exhibit such responses under conditions such as, for example, changes in the focus of specific evidence. Differentiates the epithelium of the immune system and has no immunogenic effect. Drive engraftment is a disease-hindering amplification process in which the microorganism or outcome of interest presents as an antigen and restores a particular cell of the body by producing borderline antibodies. specifically protected gender. A cold chain is a set of rules and procedures that ensure proper storage and distribution of vaccines to health services from the national level to the local level. The cold chain is connected to a refrigeration facility, allowing vaccines to be stored at recommended temperatures to maintain potency. These vaccines came over the Drug Discovery and drug research processes.


NDDS therapeutic systems
Immunization
Toxoid vaccines
Viral vector vaccines
Malignancies


Related associations and Societies:

American Association for Clinical Biochemistry Chemistry | American Biochemistry Society | American Society for Biochemistry | Association of Medical Biochemistry | Australasian Association for Clinical Biochemistry | United Nations Association of Drug Development and Drug Discovery Chemistry  | Drug-Target Association Kinetics in Drug Discovery Chemistry | Subsidiary Pharmacology conference Associations | Drug Information Association | Identification of Drug–Cancer Associations | Drug Discovery Chemistry and Development | Drug Discovery Chemistry and Development


Related Conferences:

Nano biomaterials for Drug Delivery Conference | Advances in Brain Targeted Drug Delivery Conference | Cardiovascular Pharmacology Conference | Immunization and Drug Delivery Conference | Ophthalmic Biomaterials and Drug Delivery Conference | Nanotechnology in Drug Delivery Conference | Biochemistry and Drug Design Conference | Nanotechnology and Drug Delivery Conference  | Applications of Ocular Drug Delivery Conference | Applications of Nanotechnology in Drug Delivery | Applications of Ocular Drug Delivery Conference


16. Cellular Targeting and Intercellular Delivery:

Delivery of targeted drugs to diseased tissue offers clear therapeutic benefits, such as increased strength and reduced sequelae. Advancement of specified drug delivery frameworks is supported by concerns about different drug profiles, the naming of reasonable cell culture models, and insight devices for their perception of drug discovery. Focus on cells that rely on organic data encoding devices. Although a fundamental advantage of the genetic code has not been reported recently, the peptide coding includes the origin based on the antagonists that have entered the clinical preliminaries and hardly any current evidence exists. Intracellular delivery can selectively localize molecules to target sites to maximize their efficacy and safety. Alternative routes for intracellular drug delivery and targeting have prompted extensive research and promise an exciting future for this field.


Nanocarriers

Cell-penetrating peptides

Monoclonal antibodies

Drug framework 

Peptide drug conveyance    

Salmonella-based system                                                                                          
                                                                                           


Related associations and Societies:

Drug Discovery Development Program association | Drug Development and Drug Research Society | Pharmacology & Drug Discovery Association | Drug Discovery and Development – Committee | Pharmacology and Drug Discovery Society | | American Association of Drug Discovery | American Association of Drug Discovery and development | Spain Pharmacology Association | Association of Drug Design and Pharmaceuticals | European Society of Drug Discovery


Related Conferences:

Screening and Drug Discovery conference | Biochemistry and  Drug Discovery conference | Europe Drug Discovery conference | Drug Discovery conference and events | Drug Discovery conference | Development and Drug Discovery conference | Modern Phenotypic Drug Discovery conference | Medicinal Chemistry and Drug Discovery conference | Anesthetic Research and Pharmacology conference | Behavioral Neuroscience and Psychopharmacology | Drug and Pharmacology Conference | Pharmacokinetics and Pharmacology Conference | Addiction Pharmacotherapy and  Pharmacology Conference | Cognitive Enhancers in Pharmacology Conference


17. Drug Lead Generation Strategies:

The drug lead generation depends upon the value of the drug that came over the Drug Discovery processes. Despite their small market share compared to antibody-based therapeutics, small organic molecules continue to drive most new drug approvals followed by drug discovery and drug research. Small molecules are best suited to enter cells and reach rapidly discovering intracellular disease-relevant targets. Research chemists have also recently discovered a way to allow slightly larger molecules, such as macrocyclic peptides, to reach their intracellular targets. Moreover, advances in discovery chemistry have made it possible to modulate a wider variety of disease-relevant intracellular molecules with small molecules. The importance of such generation groups in the drug discovery process and drug research has been emphasized to focus on the discovery and refinement of new lead series with improved drug-like properties. Application of productivity-enhancing integrated technologies and drug-like characterization early in the lead purification process to ensure a balanced activity profile is achieved before a full lead optimization program is implemented. It is facilitated by combining evaluations.


Phonotype and Target based screening 

GPCR-based drug discovery

Immuno Oncology targets

High throughput screening

Drug metabolites
                                                                                                                                                                                 

                                                                                                                                                                            

Related associations and Societies:

Pharmaceuticals Students' Federation | Pharmaceuticals Regulatory Authorities | Pharmaceuticals Association  | Drug Manufacturers Association of Canada  | American Association of Pharmaceuticals Scientists | Association of the British Pharmaceuticals Industry  | American Chemical Society Division of Medicinal Chemistry | Pharmacology & Drug Discovery Chemistry Research Association | Pharmacology and Drug Discovery Chemistry | Society Drug Development and drug design Society | Drug Discovery and Drug Development Committee


Related Conferences:

British Pharmacological Society Drug Discovery conference | Gene-disease and Drug Discovery conference | Parenteral Drug Discovery conference | Natural Products and Drug Discovery conference | Cardiology Research and Drug Design Conference |  Anticancer Drug Development and Clinical Trials Conference | Advanced Clinical Research and Clinical Trials Conference | Healthcare Wearable Technologies in Clinical Trials Conference | Drug Development Process and Clinical Trial Conference | Cardiology Clinical Trials Conference | Drug Development Technologies and Clinical Trial Conference | Pharmacodynamics Pharmacology Conference | Parasitology, Veterinary Medicine and Pharmacology Conference | Chemistry and Pharmacology Conference | Categories of Drugs and Pharmacology Conference | Addiction approaches and Pharmacology Conference

18. Drug Toxicology:

Drug Toxicity studies are primarily used to investigate specific adverse events and specific endpoints such as cancer, cardiotoxicity, and skin/eye irritation. Drug discovery is implied here to make a specialization drug of it. Patulin (PAT), a mycotoxin, is widespread in agricultural products. Although available research results suggest that PAT can be toxic to the nerves, immune system, and skin leading to heart, liver, and kidney damage. Trypan blue staining and Hoechst 33342 staining were used to analyze PAT, which induces apoptosis in 293 T cells. Superoxide dismutase (SOD), GSH, and malondialdehyde (MDA) were used to measure changes in the state Oxidative stress status of 293 T cells induced by PAT. Changes in reactive oxygen species (ROS) and ATP in mitochondria suggest a role for mitochondria when PAT induces cell damage and apoptosis. Through analysis of Cyt-C release assay, alteration of caspase activity, and correlation analysis, the potential mechanism of the mitochondrial apoptosis pathway was demonstrated. The results demonstrated that PAT induced cell damage significantly, and with increasing time and concentration, the cell survival rate decreased significantly. Hoechst 33342 staining and Trypan blue staining showed an increased rate of PAT-induced apoptosis. As PAT concentration increased, the activities of intracellular SOD and glutathione peroxidase decreased, and MDA content increased. Decreased intracellular ATP levels and accumulated ROS content suggest increased mitochondrial membrane permeability. Overexpression of Cyt-C triggered a cascade reaction of the enzyme caspase, leading to apoptosis. The results of the enzyme activity assay and correlation analysis indicated that caspase 3 was the most important in the cascade and was most correlated with caspase 8 and caspase 9. Drug discovery helps to make better medicinal components for this kind of effect.


Toxicogenomic
Apothecary
Immunotoxicology
Pesticide protection

 Bioanalytical sciences                                                                                                          


Related associations and Societies:

American Society for Biochemistry and Molecular Biology | American Association for Clinical Biochemistry Chemistry | American Biochemistry Society | American Society for Biochemistry | Association of Medical Biochemistry | Australasian Association for Clinical Biochemistry | United Nations Association of Drug Development and Drug Discovery Chemistry  | Drug-Target Association Kinetics in Drug Discovery Chemistry | Subsidiary Associations | Drug Information Association | Identification of Drug–Cancer Associations | Drug Discovery Chemistry and Development | Drug Discovery Chemistry and Development


Related Conference:

Applications of Behavioral Pharmacology Conference | Pharmacological Experimentation and Synaptic Pharmacology Conference | Biomedical Engineering and Pharmacology Conference  | Biotechnology and Experimental Pharmacology Conference | Anesthesia and Pharmacology Conference | Pharmaceuticals Drug and Pharmacology Conference | Pharmacovigilance and Pharmacology Conference | Nano biomaterials for Drug Delivery Conference | Advances in Brain Targeted Drug Delivery Conference | Cardiovascular Pharmacology Conference | Ophthalmic Biomaterials and Drug Delivery Conference | Nanotechnology in Drug Delivery Conference | Biochemistry and Drug Design Conference | Nanotechnology and Drug Delivery Conference

Market Analysis

The market size of the global drug discovery was valued at about 74.96 billion in 2021 and around 161.76 USD by 2030 is to be expected, and its growing at a CAGR of 8.9% from the period 2021 to 2030. The small molecule segment-type drug discovery dominated the market in 2020. It makes the demand for small molecule drugs in the healthcare field. The increased awareness of small molecule drugs has increased the investment in them.

 

                                                    Market Size of Drug Discovery, 2020 To 2030 (USD Billion)

 

 

 

Some leading countries in drug discovery are the USA, Europe, Canada, China, and Germany.
The increased spending on R&D by
pharmaceuticals and biologics firms around the world is the main factor driving the market for drug discovery services globally. The growing elderly population and the prevalence of various diseases are the two main factors driving the need for pharmaceutical medications.
 
During the projection period of 2021 to 2026, the global market for
drug discovery services is anticipated to grow at a CAGR of 14.3%, from USD 16.1 billion in 2021 to USD 31.4 billion by 2022 to 2026.

 

According to the International Federation of Pharmaceutical Manufacturers & Associations, the pharmaceutical industry spent around US$150 billion in drug discovery research & development activities. It is estimated that on average, a pharmaceutical company spends around 17% of its revenues on research & development. Therefore, the rapidly growing pharmaceuticals industry and surging investments by them in R&D are expected to drive the growth of the global drug discovery services market during the forecast period. Venture capital deal activity and investment flow in the US have accelerated over the past two years, with more than 2,000 deals valued at $47 billion in 2021 as interest in life sciences grows. Additionally, the top 15 pharmaceutical companies will invest $133 billion in R&D spending in 2021, up 44% from 2016.

The European drug discovery market is valued at USD 14.8 billion in 2020 and is expected to grow by 8.3% due to rising healthcare costs, rising R&D spending, and patent expiry. The Europe CRO services market was valued at USD 16.9 billion in 2021. The market is projected to grow from USD 19.68 billion in 2022 to USD 35.91 billion by 2029, exhibiting a CAGR of 9.0% during the forecast period.


 

This statistic presents the projected annual revenue of global Contract Research Organizations (CROs) by location from 2016 to 2021. In 2016, Asia-Pacific CRO revenue was estimated at US$4.9 billion, compared to around US$30.5 billion in the rest of the world.

 

The market grew by 27.4% in 2020 compared to 2021. Due to the impact of COVID-19 on his CRO services, his D44 sales increased by an estimated 3.4% in 2020, based on the analysis of various parameters. In Europe, pharmaceutical industry R&D spending reached US$186 billion in 2019, compared to US$136 billion in 2012.

 

Large numbers of expired patents reduced R&D productivity, and high drug design costs are forcing large pharmaceutical companies to outsource their R&D activities to other locations. Asia is proving to be the preferred destination to conduct its drug development activities. The availability of a large patient population, low costs, R&D personnel, and a favorable regulatory environment are the main drivers for Asia's transformation into a hub for R&D activities.

 

Several contract research organizations (CROs) have set up shops in Asia to provide trial monitoring, project management, data management, safety reporting, drug delivery, and laboratory services. center experience. Many leading Western multinationals have moved their R&D activities to Asian countries, including Glaxo Smith Kline, Pfizer, and Novartis.

 

The Asia Pacific drug development market size is estimated to reach 37.62 billion in 2018 and is expected to reach a CAGR of 6.54% during the forecast period. Changing market dynamics such as steady growth in the pharmaceutical market coupled with saturated growth in established markets are driving the growth of the market. Furthermore, the inflow of investment capital into the Asian pharmaceutical industry from the Western region has provided significant business expansion opportunities for new entrants to expand their business.

 

Companies have effectively moved from a “speed and cost” based value proposition in clinical trials to an added value proposition. This includes the transition from the early stages of molecular development licensing to the later stages of licensing. In addition, the trend is being applied toward service model fees as well as risk sharing and partnerships.


The Canadian Pharmaceutical Market is valued at $29,305.1 million in 2021. It is expected to reach $39,427.4 million by 2027, achieving a CAGR of 5.26% during 2022-2027.

 

 

In 2018, the sector added nearly $15 billion in value added (gross domestic product) to the Canadian economy and supported more than 100,000 full-time equivalents (FTE) jobs in Canada. Additionally, it spent between $1.5 billion and $2.0 billion on research and development. The sector has spent $1 billion on in-house research and development in Canada while spending $950 million on outsourced research and development work in Canada and abroad.

 

Statistics Canada typically reports in-house and outsourced R&D as separate values, as adding in-house and outsourcing costs can result in double-counting outsourced domestic R&D. While it is not possible to give an exact estimate of the total amount of R&D performed by the pharmaceutical R&D sector for 2018, it is estimated to be between $1.5 billion and $2.0 billion.

Past Conference Report

Drug development 2021 was a fantastic success thanks in large part to the outstanding keynote speakers, attendees, students, media partners, and delegates who make the event an unforgettable one.

2021 December 8–9 saw the "4th International Conference on Drug Discovery and Drug Development". There were panel discussions with researchers and other academics during this two-day event as well as general keynote talks from research experts.

For the purpose of discussing drug discovery and its role in the healthcare, treatment, and prevention of the pandemic, Drug development 2021 provided a forum for all scientists, professional educators, cardiologists, surgeons, biomedical advisers, researchers, and clinical benefits specialists.

Eminent keynote speakers from numerous organizations and institutes shared their perspectives and social commentary throughout the conference, which had the topic "Pioneering the inventive heights in the field of drug discovery and development."

Organizing Committee
OCM Member
Prof. Dr. Alireza Heidari, Ph.D., D.Sc.
President of American International Standards Institute, Chemistry
California South University
California, USA
OCM Member
Prof. Alain L. Fymat
President/CEO and Professor, Radiology
International Institute of Medicine and Science
California, USA
OCM Member
Prof. (Dr.) Bechan Sharma
Professor of Biochemistry & Chairman, Department of Biochemistry
University of Allahabad
Allahabad, India
Renowned Speakers

To Collaborate Scientific Professionals around the World

Conference Date March 13-15, 2023
Speaker Oppurtunity
Poster Oppurtunity Available
e-Poster Oppurtunity Available
Join The Discussion

Contact Desk

General Queries

Daisy Hawkins

daisyhawkins15@gmail.com

+44 20 3769 1755

Registration Queries

Daisy Hawkins

daisyhawkins15@gmail.com

+44 20 3769 1755

Exhibitor Queries

Daisy Hawkins

daisyhawkins15@gmail.com

+44 20 3769 1755

Previous Conferences

Special Issues
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
Media Partners

Allied Academies Global Conference Directory

Mail us at

General Queries
daisyhawkins15@gmail.com
Registration Queries
daisyhawkins15@gmail.com
Exhibitor Queries
daisyhawkins15@gmail.com
More details about sponsorship:sponsors@alliedacademies.com

Terms and Conditions

Responsibility

Delegates are personally responsible for their belongings at the venue. The Organizers will not be held responsible for any stolen or missing items belonging to Delegates, Speakers or Attendees; due to any reason whatsoever.

Insurance

Registration fees do not include insurance of any kind.

Transportation

Please note that any (or) all transportation and parking is the responsibility of the registrant.

Press/Media

Press permission must be obtained from Allied Academies Conferences Organizing Committee prior to the event. The press will not quote speakers or delegates unless they have obtained their approval in writing. The Allied Academies is an objective third-party nonprofit organization. This conference is not associated with any commercial meeting company.

Requesting an Invitation Letter

For security purposes, letter of invitation will be sent only to those individuals who had registered for the conference. Once your registration is complete, please contact drugdiscovery@alliedconferences.org to request a personalized letter of invitation.

Regarding refunds, all bank charges will be for the registrants account.

This cancellation policy was last updated on December 12, 2016.

Cancellation, Postponement and Transfer of Registration

All cancellations or modifications of registration must be made in writing to drugdiscovery@alliedconferences.org

Cancellation Policy

If Allied Academies cancels this event for any reason, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Allied Academies event which must occur within one year from the date of cancellation.

Postponement

If Allied Academies postpones an event for any reason and you are unable or unwilling to attend on rescheduled dates, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Allied Academies event which must occur within one year from the date of postponement.

Transfer of registration

All fully paid registrations are transferable to other persons from the same organization, if registered person is unable to attend the event. Transfers must be made by the registered person in writing to drugdiscovery@alliedconferences.org . Details must be included the full name of replacement person, their title, contact phone number and email address. All other registration details will be assigned to the new person unless otherwise specified.

Registration can be transferred to one conference to another conference of Allied Academies if the person is unable to attend one of conferences.

However, Registration cannot be transferred if it is intimated within 14 days of respective conference.

The transferred registrations will not be eligible for Refund.

Visa Information

Keeping in view of increased security measures, we would like to request all the participants to apply for Visa as soon as possible.

Allied Academies will not directly contact embassies and consulates on behalf of visa applicants. All delegates or invitees should apply for Business Visa only.

Important note for failed visa applications: Visa issues cannot come under the consideration of cancellation policy of Allied Academies, including the inability to obtain a visa.

Refund Policy:

If the registrant is unable to attend, and is not in a position to transfer his/her participation to another person or event, then the following refund arrangements apply:

Keeping in view of advance payments towards Venue, Printing, Shipping, Hotels and other overheads, we had to keep Refund Policy is as following slabs-

  • Before 60 days of the conference: Eligible for Full Refund less $100 service Fee
  • Within 60-30 days of Conference: Eligible for 50% of payment Refund
  • Within 30 days of Conference: Not eligible for Refund
  • E-Poster Payments will not be refunded.

Accommodation Cancellation Policy:

Accommodation Providers (Hotels) have their own cancellation policies, and they generally apply when cancellations are made less than 30 days prior to arrival. Please contact us as soon as possible, if you wish to cancel or amend your accommodation. Allied Academies will advise the cancellation policy of your accommodation provider, prior to cancelling or amending your booking, to ensure you are fully aware of any non-refundable deposits.

 

Highlights from last year's Convention

Authorization Policy


Copyright © 2023-2024 Allied Academies, All Rights Reserved.